IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerchione, Claudio, Romano, Alessandra, Daver, Naval, DiNardo, Courtney, Jabbour, Elias Joseph, Konopleva, Marina, Ravandi-Kashani, Farhad, Kadia, Tapan, Martelli, Maria Paola, Isidori, Alessandro, Martinelli, Giovanni, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063727/
https://www.ncbi.nlm.nih.gov/pubmed/33898313
http://dx.doi.org/10.3389/fonc.2021.639387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063727/
https://www.ncbi.nlm.nih.gov/pubmed/33898313
http://dx.doi.org/10.3389/fonc.2021.639387

Ejemplares similares